Clinical Trial Update: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 maintenance trial results for mirikizumab in adults with moderately to severely active ulcerative colitis have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2022-11-25